130 related articles for article (PubMed ID: 36326016)
21. Iris melanoma: Prognostication for metastasis.
Melendez-Moreno A; Yeşiltaş YS; Wrenn J; Singh AD
Surv Ophthalmol; 2023; 68(5):957-963. PubMed ID: 37207703
[TBL] [Abstract][Full Text] [Related]
22. Iris melanoma: risk factors for metastasis in 169 consecutive patients.
Shields CL; Shields JA; Materin M; Gershenbaum E; Singh AD; Smith A
Ophthalmology; 2001 Jan; 108(1):172-8. PubMed ID: 11150284
[TBL] [Abstract][Full Text] [Related]
23. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.
Riechardt AI; Klein JP; Cordini D; Heufelder J; Rehak M; Seibel I; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1325-1332. PubMed ID: 29464331
[TBL] [Abstract][Full Text] [Related]
24. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
[TBL] [Abstract][Full Text] [Related]
25. Iris melanoma: Review of clinical features, risks, management, and outcomes.
Cherkas E; Kalafatis NE; Marous MR; Shields CL
Clin Dermatol; 2024; 42(1):62-70. PubMed ID: 37865279
[TBL] [Abstract][Full Text] [Related]
26. Impact of iris color on uveal melanoma-related outcomes in 7245 patients at a single ocular oncology center.
Zaloga AR; DeYoung C; Kurian DE; Card KR; Caudill GB; Zeiger JS; Shields CL
Asia Pac J Ophthalmol (Phila); 2024; 13(1):100031. PubMed ID: 38383076
[TBL] [Abstract][Full Text] [Related]
27. A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models.
Gill VT; Sabazade S; Herrspiegel C; Ewens KG; Opalko A; Dan N; Christersdottir T; Berg Rendahl A; Shields CL; Seregard S; Ganguly A; Stålhammar G
Acta Ophthalmol; 2023 Feb; 101(1):34-48. PubMed ID: 35801361
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetics of iris melanomas: disparity with other uveal tract melanomas.
Sisley K; Brand C; Parsons MA; Maltby E; Rees RC; Rennie IG
Cancer Genet Cytogenet; 1998 Mar; 101(2):128-33. PubMed ID: 9494614
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study.
Khan S; Finger PT; Yu GP; Razzaq L; Jager MJ; de Keizer RJ; Sandkull P; Seregard S; Gologorsky D; Schefler AC; Murray TG; Kivelä T; Giuliari GP; McGowan H; Simpson ER; Corriveau C; Coupland SE; Damato BE
Arch Ophthalmol; 2012 Jan; 130(1):57-64. PubMed ID: 21911649
[TBL] [Abstract][Full Text] [Related]
30. Proton beam radiotherapy of iris melanoma.
Damato B; Kacperek A; Chopra M; Sheen MA; Campbell IR; Errington RD
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):109-15. PubMed ID: 16111578
[TBL] [Abstract][Full Text] [Related]
31. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients.
Naumann GO; Rummelt V
Ophthalmology; 1996 Dec; 103(12):2017-27; discussion 2027-8. PubMed ID: 9003335
[TBL] [Abstract][Full Text] [Related]
32. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.
Walter SD; Chao DL; Feuer W; Schiffman J; Char DH; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):734-40. PubMed ID: 27123792
[TBL] [Abstract][Full Text] [Related]
34. Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.
Riechardt AI; Karle B; Cordini D; Heufelder J; Budach V; Joussen AM; Gollrad J
Strahlenther Onkol; 2017 Nov; 193(11):943-950. PubMed ID: 28631017
[TBL] [Abstract][Full Text] [Related]
35. Iris melanocytic tumours in New Zealand/Aotearoa: presentation, management and outcome in a high UV exposure environment.
Rapata MEJ; Zhang J; Cunningham WJ; Hadden PW; Patel DV; McGhee CNJ
Eye (Lond); 2023 Mar; 37(4):692-699. PubMed ID: 35338357
[TBL] [Abstract][Full Text] [Related]
36. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
37. Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors.
Kim EA; Salazar D; McCannel CA; Kamrava M; Demanes DJ; Lamb J; Caprioli J; McCannel TA
J Glaucoma; 2020 Jan; 29(1):1-10. PubMed ID: 31688338
[TBL] [Abstract][Full Text] [Related]
38. Conservative management of suspicious melanocytic lesions of the iris.
Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
[TBL] [Abstract][Full Text] [Related]
39. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract][Full Text] [Related]
40. Chromosomal aberrations in iris melanomas.
Mensink HW; Vaarwater J; de Keizer RJ; de Wolff-Rouendaal D; Mooy CM; de Klein A; Paridaens D
Br J Ophthalmol; 2011 Mar; 95(3):424-8. PubMed ID: 20881029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
